Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

NEXT STORY
AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc.
PREV STORY
Teleflex Announces Real-World Clinical Data Presentations of the UroLift® System at the 36th Annual European Association of Urology Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Investigator-led study has commenced dosingImmunotherapy candidate CV301 is being assessed in combination with checkpoint ...

author_avatar
NASDAQ Market News

Protech Home Medical Announces Continued Business Excellence During COVID-19 Pandemic and Comments on CMS Decision to Remove Non-Invasive Ventilators from Competitive Bidding Program

author_avatar
NASDAQ Market News

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

author_avatar
NASDAQ Market News